Sort   by:  
 Page size 
MetabolomicsMetabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease

BACKGROUND: One-third of inflammatory bowel disease (IBD) patients show no response to infliximab (IFX) induction therapy, and approximately half of patients responding become unresponsive over time. Thus, identification of potential treatment response biomarkers are of great cl...

2022-01-13 | MTBLS239 | MetaboLights
MetabolomicsUPLC-QTOF-MS-Based Plasma Lipidomic Profiling Reveals Biomarkers for Inflammatory Bowel Disease Diagnosis
Identification of new biomarkers may help in the early diagnosis of inflammatory bowel disease (IBD). In this study, ultrahigh-performance liquid chromatography equipped with quadrupole time-of-flight mass spectrometry (UPLC-QTOF-MS) was used to analyze the untargeted lipidomics and compare plasma l...
2021-10-18 | MTBLS1183 | MetaboLights
MetabolomicsMicrobiome and metabolome features in inflammatory bowel disease via multi-omics integration analyses across cohorts

The perturbations of the gut microbiota and metabolites are closely associated with the progression of inflammatory bowel disease (IBD). However, inconsistent findings across studies impede a comprehensive understanding of their roles in IBD and their potential as reliable diagnostic biomarkers. ...

2026-01-28 | MTBLS8713 | MetaboLights
MetabolomicsUntargeted metabolomic analysis in cats with naturally occurring inflammatory bowel disease and alimentary small cell lymphoma
Feline chronic enteropathy (CE) is a common gastrointestinal disorder in cats and mainly comprises inflammatory bowel disease (IBD) and small cell lymphoma (SCL). Differentiation between IBD and SCL can be diagnostically challenging. We characterized the fecal metabolome of 14 healthy cats and 22 ca...
2021-07-13 | MTBLS440 | MetaboLights
MetabolomicsBioinspired Nanozyme-Exoskeletonized Yeast-derived Polysaccharides for Treating Comorbid Anxiety and Depression in Inflammatory Bowel Disease

Inflammatory bowel disease (IBD) is a chronic condition frequently accompanied by psychological comorbidities, such as anxiety and depression. Although current treatments may alleviate some of these symptoms, the intricate pathogenesis of these comorbidities highlights an urgent need for the deve...

2026-03-24 | MTBLS14127 | MetaboLights
MetabolomicsIntestinal Microbe-Metabolite Network Associated with The Efficacy of Fecal Microbiota Transplantation Therapy in Inflammatory Bowel Disease

BACKGROUND: Inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), is a type of recurrent and incurable disease, which can lead to the loss of workability, increase cancer risk and bring serious economic burden to patients. Abnormal intestin...

2026-03-11 | MTBLS3909 | MetaboLights
MetabolomicsLongitudinal Metabolomics of the Human Microbiome in Inflammatory Bowel Disease
Not available
ORGANISM(S): Homo sapiens 
ST000923 | MetabolomicsWorkbench
MetabolomicsGut microbiome structure and metabolic activity in inflammatory bowel disease
Not available
ORGANISM(S): Homo sapiens 
ST001000 | MetabolomicsWorkbench
MetabolomicsLongitudinal Characterization of the Fecal Metabolome in Dogs with Idiopathic Inflammatory Bowel Disease
Not available
ORGANISM(S): Canis lupus familiaris 
ST001247 | MetabolomicsWorkbench
ModelsInflammatory Bowel Disease (IBD) Model
A Systems Pharmacology model for Inflammatory Bowel Disease
8558 | Cell Collective
Sort   by:  
 Page size